FAP and neoplasm: The imaging and biodistribution analysis of mice co-injected [68Ga]Ga-SB04028 with FAPI-04 (0.5 mg/mouse) revealed a ~97% reduction in the tumor uptake (10.1 ± 0.42 %ID/g vs. 0.30 ± 0.04 %ID/g) substantiating in vivo FAP specificity of our lead candidate [68Ga]Ga-SB04028 (Figure 3 and Figure 4, Table S1).